Shopping Cart 0
Cart Subtotal
AED 0

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Eisai Co Ltd (4523)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 27,2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia

Jul 19,2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018

Jul 18,2018: Eisai supports relief efforts for flooding in western Japan

Jul 04,2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment

Jun 13,2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Eisai Co Ltd-Key Facts 6

Eisai Co Ltd-Key Employees 7

Eisai Co Ltd-Key Employee Biographies 10

Eisai Co Ltd-Major Products and Services 11

Eisai Co Ltd-History 13

Eisai Co Ltd-Company Statement 21

Eisai Co Ltd-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Joint Venture 25

Section 2-Company Analysis 26

Company Overview 26

Eisai Co Ltd-Business Description 27

Product Category: Neurology Products 27

Overview 27

Performance 27

Product Category: Oncology Products 27

Overview 27

Performance 27

Product Category: Others 28

Performance 28

Product Category: Americas Pharmaceutical Business 28

Overview 28

Performance 28

Product Category: Asia and Latin America Pharmaceutical Business 28

Overview 28

Performance 28

Product Category: China Pharmaceutical Business 29

Overview 29

Performance 29

Product Category: EMEA Pharmaceutical Business 29

Overview 29

Performance 29

Product Category: Japan Pharmaceutical Business 29

Overview 29

Performance 29

Product Category: Other Business 29

Overview 29

Performance 30

R&D Overview 30

Eisai Co Ltd-Corporate Strategy 31

Eisai Co Ltd-SWOT Analysis 32

SWOT Analysis-Overview 32

Eisai Co Ltd-Strengths 32

Eisai Co Ltd-Weaknesses 33

Eisai Co Ltd-Opportunities 34

Eisai Co Ltd-Threats 35

Eisai Co Ltd-Key Competitors 36

Section 3-Company Financial Ratios 37

Financial Ratios-Capital Market Ratios 37

Financial Ratios-Annual Ratios 38

Performance Chart 41

Financial Performance 41

Financial Ratios-Interim Ratios 42

Financial Ratios-Ratio Charts 43

Section 4-Company's Lifesciences Financial Deals and Alliances 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45

Eisai Co Ltd, Recent Deals Summary 46

Section 5-Company's Recent Developments 47

Jul 27, 2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia 47

Jul 19, 2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018 51

Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 52

Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 53

Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 54

Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 55

Jun 13, 2018: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research Using Novel Nucleic Acid Synthesis And Delivery Technologies Concluded 56

Feb 26, 2018: Launch of Dementia Support Insurance to Provide for Dementia in Japan 57

Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 58

Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 59

Section 6-Appendix 60

Methodology 60

Ratio Definitions 60

About GlobalData 64

Contact Us 64

Disclaimer 64


List Of Figure

List of Figures

Eisai Co Ltd, Performance Chart (2014-2018) 41

Eisai Co Ltd, Ratio Charts 43

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 45


List Of Table

List of Tables

Eisai Co Ltd, Key Facts 6

Eisai Co Ltd, Key Employees 7

Eisai Co Ltd, Key Employee Biographies 10

Eisai Co Ltd, Major Products and Services 11

Eisai Co Ltd, History 13

Eisai Co Ltd, Subsidiaries 22

Eisai Co Ltd, Joint Venture 25

Eisai Co Ltd, Key Competitors 36

Eisai Co Ltd, Ratios based on current share price 37

Eisai Co Ltd, Annual Ratios 38

Eisai Co Ltd, Annual Ratios (Cont...1) 39

Eisai Co Ltd, Annual Ratios (Cont...2) 40

Eisai Co Ltd, Interim Ratios 42

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45

Eisai Co Ltd, Recent Deals Summary 46

Currency Codes 60

Capital Market Ratios 60

Equity Ratios 61

Profitability Ratios 61

Cost Ratios 62

Liquidity Ratios 62

Leverage Ratios 63

Efficiency Ratios 63

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Eisai Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Daiichi Sankyo Inc

Mochida Pharmaceutical Co Ltd

Nippon Kayaku Co Ltd

Ono Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Eisai Co Ltd (4523)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 27,2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia

Jul 19,2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018

Jul 18,2018: Eisai supports relief efforts for flooding in western Japan

Jul 04,2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment

Jun 13,2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Eisai Co Ltd-Key Facts 6

Eisai Co Ltd-Key Employees 7

Eisai Co Ltd-Key Employee Biographies 10

Eisai Co Ltd-Major Products and Services 11

Eisai Co Ltd-History 13

Eisai Co Ltd-Company Statement 21

Eisai Co Ltd-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Joint Venture 25

Section 2-Company Analysis 26

Company Overview 26

Eisai Co Ltd-Business Description 27

Product Category: Neurology Products 27

Overview 27

Performance 27

Product Category: Oncology Products 27

Overview 27

Performance 27

Product Category: Others 28

Performance 28

Product Category: Americas Pharmaceutical Business 28

Overview 28

Performance 28

Product Category: Asia and Latin America Pharmaceutical Business 28

Overview 28

Performance 28

Product Category: China Pharmaceutical Business 29

Overview 29

Performance 29

Product Category: EMEA Pharmaceutical Business 29

Overview 29

Performance 29

Product Category: Japan Pharmaceutical Business 29

Overview 29

Performance 29

Product Category: Other Business 29

Overview 29

Performance 30

R&D Overview 30

Eisai Co Ltd-Corporate Strategy 31

Eisai Co Ltd-SWOT Analysis 32

SWOT Analysis-Overview 32

Eisai Co Ltd-Strengths 32

Eisai Co Ltd-Weaknesses 33

Eisai Co Ltd-Opportunities 34

Eisai Co Ltd-Threats 35

Eisai Co Ltd-Key Competitors 36

Section 3-Company Financial Ratios 37

Financial Ratios-Capital Market Ratios 37

Financial Ratios-Annual Ratios 38

Performance Chart 41

Financial Performance 41

Financial Ratios-Interim Ratios 42

Financial Ratios-Ratio Charts 43

Section 4-Company's Lifesciences Financial Deals and Alliances 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45

Eisai Co Ltd, Recent Deals Summary 46

Section 5-Company's Recent Developments 47

Jul 27, 2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia 47

Jul 19, 2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018 51

Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 52

Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 53

Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 54

Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 55

Jun 13, 2018: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research Using Novel Nucleic Acid Synthesis And Delivery Technologies Concluded 56

Feb 26, 2018: Launch of Dementia Support Insurance to Provide for Dementia in Japan 57

Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 58

Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 59

Section 6-Appendix 60

Methodology 60

Ratio Definitions 60

About GlobalData 64

Contact Us 64

Disclaimer 64


List Of Figure

List of Figures

Eisai Co Ltd, Performance Chart (2014-2018) 41

Eisai Co Ltd, Ratio Charts 43

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 45


List Of Table

List of Tables

Eisai Co Ltd, Key Facts 6

Eisai Co Ltd, Key Employees 7

Eisai Co Ltd, Key Employee Biographies 10

Eisai Co Ltd, Major Products and Services 11

Eisai Co Ltd, History 13

Eisai Co Ltd, Subsidiaries 22

Eisai Co Ltd, Joint Venture 25

Eisai Co Ltd, Key Competitors 36

Eisai Co Ltd, Ratios based on current share price 37

Eisai Co Ltd, Annual Ratios 38

Eisai Co Ltd, Annual Ratios (Cont...1) 39

Eisai Co Ltd, Annual Ratios (Cont...2) 40

Eisai Co Ltd, Interim Ratios 42

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45

Eisai Co Ltd, Recent Deals Summary 46

Currency Codes 60

Capital Market Ratios 60

Equity Ratios 61

Profitability Ratios 61

Cost Ratios 62

Liquidity Ratios 62

Leverage Ratios 63

Efficiency Ratios 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Eisai Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Daiichi Sankyo Inc

Mochida Pharmaceutical Co Ltd

Nippon Kayaku Co Ltd

Ono Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd